Literature DB >> 31989783

New data highlighting the efficacy and safety outcomes of third-generation EGFR-TKI in NSCLC patients with rare EGFR mutations.

Weisan Zhang1,2, Fengtan Li3, Wenyuan Gao1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 31989783      PMCID： PMC7049494          DOI： 10.1111/1759-7714.13334

Source DB:  PubMed          Journal:  Thorac Cancer        ISSN： 1759-7706            Impact factor:   3.500


× No keyword cloud information.
  17 in total

1.  Non-responsiveness to gefitinib in a patient with lung adenocarcinoma having rare EGFR mutations S768I and V769L.

Authors:  Hajime Asahina; Koichi Yamazaki; Ichiro Kinoshita; Hiroshi Yokouchi; Hirotoshi Dosaka-Akita; Masaharu Nishimura
Journal:  Lung Cancer       Date:  2006-10-12       Impact factor: 5.705

Review 2.  Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship.

Authors:  Julian R Molina; Ping Yang; Stephen D Cassivi; Steven E Schild; Alex A Adjei
Journal:  Mayo Clin Proc       Date:  2008-05       Impact factor: 7.616

3.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

Authors:  Tony S Mok; Yi-Long Wu; Sumitra Thongprasert; Chih-Hsin Yang; Da-Tong Chu; Nagahiro Saijo; Patrapim Sunpaweravong; Baohui Han; Benjamin Margono; Yukito Ichinose; Yutaka Nishiwaki; Yuichiro Ohe; Jin-Ji Yang; Busyamas Chewaskulyong; Haiyi Jiang; Emma L Duffield; Claire L Watkins; Alison A Armour; Masahiro Fukuoka
Journal:  N Engl J Med       Date:  2009-08-19       Impact factor: 91.245

4.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

5.  CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3).

Authors:  Yi-Long Wu; Myung-Ju Ahn; Marina Chiara Garassino; Ji-Youn Han; Nobuyuki Katakami; Hye Ryun Kim; Rachel Hodge; Paramjit Kaur; Andrew P Brown; Dana Ghiorghiu; Vassiliki A Papadimitrakopoulou; Tony S K Mok
Journal:  J Clin Oncol       Date:  2018-07-30       Impact factor: 44.544

6.  Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.

Authors:  James Chih-Hsin Yang; Myung-Ju Ahn; Dong-Wan Kim; Suresh S Ramalingam; Lecia V Sequist; Wu-Chou Su; Sang-We Kim; Joo-Hang Kim; David Planchard; Enriqueta Felip; Fiona Blackhall; Daniel Haggstrom; Kiyotaka Yoh; Silvia Novello; Kathryn Gold; Tomonori Hirashima; Chia-Chi Lin; Helen Mann; Mireille Cantarini; Serban Ghiorghiu; Pasi A Jänne
Journal:  J Clin Oncol       Date:  2017-02-21       Impact factor: 44.544

7.  Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics?

Authors:  Rui-Mei Feng; Yi-Nan Zong; Su-Mei Cao; Rui-Hua Xu
Journal:  Cancer Commun (Lond)       Date:  2019-04-29

8.  The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706).

Authors:  Zhonghan Zhang; Fan Luo; Yang Zhang; Yuxiang Ma; Shaodong Hong; Yunpeng Yang; Wenfeng Fang; Yan Huang; Li Zhang; Hongyun Zhao
Journal:  Cancer Commun (Lond)       Date:  2019-11-07

9.  Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09).

Authors:  Jang Ho Cho; Sung Hee Lim; Ho Jung An; Ki Hwan Kim; Keon Uk Park; Eun Joo Kang; Yoon Hee Choi; Mi Sun Ahn; Myung Hee Lee; Jong-Mu Sun; Se-Hoon Lee; Jin Seok Ahn; Keunchil Park; Myung-Ju Ahn
Journal:  J Clin Oncol       Date:  2019-12-11       Impact factor: 44.544

10.  Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

Authors:  Jean-Charles Soria; Yuichiro Ohe; Johan Vansteenkiste; Thanyanan Reungwetwattana; Busyamas Chewaskulyong; Ki Hyeong Lee; Arunee Dechaphunkul; Fumio Imamura; Naoyuki Nogami; Takayasu Kurata; Isamu Okamoto; Caicun Zhou; Byoung Chul Cho; Ying Cheng; Eun Kyung Cho; Pei Jye Voon; David Planchard; Wu-Chou Su; Jhanelle E Gray; Siow-Ming Lee; Rachel Hodge; Marcelo Marotti; Yuri Rukazenkov; Suresh S Ramalingam
Journal:  N Engl J Med       Date:  2017-11-18       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.